231 related articles for article (PubMed ID: 23672863)
1. Progress in platelet blockers: the target is the P2Y12 receptor.
Patel PA; Lane B; Augoustides JG
J Cardiothorac Vasc Anesth; 2013 Jun; 27(3):620-4. PubMed ID: 23672863
[TBL] [Abstract][Full Text] [Related]
2. Pharmacology and clinical trials of reversibly-binding P2Y12 inhibitors.
Storey RF
Thromb Haemost; 2011 May; 105 Suppl 1():S75-81. PubMed ID: 21479343
[TBL] [Abstract][Full Text] [Related]
3. State of the art of new P2Y12 antagonists.
Cattaneo M; Podda GM
Intern Emerg Med; 2010 Oct; 5(5):385-91. PubMed ID: 20177818
[TBL] [Abstract][Full Text] [Related]
4. Thienopyridines and other ADP-receptor antagonists.
Bernlochner I; Sibbing D
Handb Exp Pharmacol; 2012; (210):165-98. PubMed ID: 22918731
[TBL] [Abstract][Full Text] [Related]
5. [Myocardial infarction: Role of new antiplatelet agents].
Silvain J; Bellemain A; Ecollan P; Montalescot G; Collet JP
Presse Med; 2011 Jun; 40(6):615-24. PubMed ID: 21511430
[TBL] [Abstract][Full Text] [Related]
6. Bleeding manifestations of congenital and drug-induced defects of the platelet P2Y12 receptor for adenosine diphosphate.
Cattaneo M
Thromb Haemost; 2011 May; 105 Suppl 1():S67-74. PubMed ID: 21479342
[TBL] [Abstract][Full Text] [Related]
7. A clopidogrel-insensitive inducible pool of P2Y12 receptors contributes to thrombus formation: inhibition by elinogrel, a direct-acting, reversible P2Y12 antagonist.
Haberstock-Debic H; Andre P; Mills S; Phillips DR; Conley PB
J Pharmacol Exp Ther; 2011 Oct; 339(1):54-61. PubMed ID: 21730013
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of ticagrelor pharmacodynamic interactions with reversibly binding or non-reversibly binding P2Y(12) antagonists in an ex-vivo canine model.
Ravnefjord A; Weilitz J; Emanuelsson BM; van Giezen JJ
Thromb Res; 2012 Oct; 130(4):622-8. PubMed ID: 22909827
[TBL] [Abstract][Full Text] [Related]
9. Antiplatelet effects of aspirin vary with level of P2Y₁₂ receptor blockade supplied by either ticagrelor or prasugrel.
Kirkby NS; Leadbeater PD; Chan MV; Nylander S; Mitchell JA; Warner TD
J Thromb Haemost; 2011 Oct; 9(10):2103-5. PubMed ID: 21812912
[No Abstract] [Full Text] [Related]
10. P2Y12 platelet receptors: importance in percutaneous coronary intervention.
Falcão FJ; Carvalho L; Chan M; Alves CM; Carvalho AC; Caixeta AM
Arq Bras Cardiol; 2013 Sep; 101(3):277-82. PubMed ID: 23917456
[TBL] [Abstract][Full Text] [Related]
11. Pharmacodynamic effects of cangrelor on platelet P2Y12 receptor-mediated signaling in prasugrel-treated patients.
Rollini F; Franchi F; Tello-Montoliu A; Patel R; Darlington A; Ferreiro JL; Cho JR; Muñiz-Lozano A; Desai B; Zenni MM; Guzman LA; Bass TA; Angiolillo DJ
JACC Cardiovasc Interv; 2014 Apr; 7(4):426-34. PubMed ID: 24630878
[TBL] [Abstract][Full Text] [Related]
12. Dyspnea and reversibility of antiplatelet agents: ticagrelor, elinogrel, cangrelor, and beyond.
Serebruany VL; Sibbing D; DiNicolantonio JJ
Cardiology; 2014; 127(1):20-4. PubMed ID: 24192670
[TBL] [Abstract][Full Text] [Related]
13. Cangrelor inhibits the binding of the active metabolites of clopidogrel and prasugrel to P2Y12 receptors in vitro.
Judge HM; Buckland RJ; Jakubowski JA; Storey RF
Platelets; 2016; 27(3):191-5. PubMed ID: 26270719
[TBL] [Abstract][Full Text] [Related]
14. Clinical effects and outcomes with new P2Y12 inhibitors in ACS.
Collet JP; O'Connor S
Fundam Clin Pharmacol; 2012 Feb; 26(1):16-8. PubMed ID: 21895760
[TBL] [Abstract][Full Text] [Related]
15. [Recent advances on the studies of the platelet's inhibition and aggregation. State of the art of new P2Y12 antagonists].
Cattaneo GJ; Podda GM; Cattaneo M
Recenti Prog Med; 2011 Apr; 102(4):150-5. PubMed ID: 21572491
[TBL] [Abstract][Full Text] [Related]
16. ADP-receptor inhibitors in the perioperative period: the good, the bad, and the ugly.
Oprea AD; Popescu WM
J Cardiothorac Vasc Anesth; 2013 Aug; 27(4):779-95. PubMed ID: 23648080
[No Abstract] [Full Text] [Related]
17. A randomized, double-blind, active-controlled phase 2 trial to evaluate a novel selective and reversible intravenous and oral P2Y12 inhibitor elinogrel versus clopidogrel in patients undergoing nonurgent percutaneous coronary intervention: the INNOVATE-PCI trial.
Welsh RC; Rao SV; Zeymer U; Thompson VP; Huber K; Kochman J; McClure MW; Gretler DD; Bhatt DL; Gibson CM; Angiolillo DJ; Gurbel PA; Berdan LG; Paynter G; Leonardi S; Madan M; French WJ; Harrington RA;
Circ Cardiovasc Interv; 2012 Jun; 5(3):336-46. PubMed ID: 22647518
[TBL] [Abstract][Full Text] [Related]
18. Mode of action of P2Y(12 ) antagonists as inhibitors of platelet function.
Iyú D; Glenn JR; White AE; Fox SC; van Giezen H; Nylander S; Heptinstall S
Thromb Haemost; 2011 Jan; 105(1):96-106. PubMed ID: 20941457
[TBL] [Abstract][Full Text] [Related]
19. Ticagrelor--a new platelet aggregation inhibitor in patients with acute coronary syndromes. An improvement of other inhibitors?
Kowalczyk M; Banach M; Mikhailidis DP; Hannam S; Rysz J
Med Sci Monit; 2009 Dec; 15(12):MS24-30. PubMed ID: 19946242
[TBL] [Abstract][Full Text] [Related]
20. P2Y₁₂ and EP3 antagonists promote the inhibitory effects of natural modulators of platelet aggregation that act via cAMP.
Iyú D; Glenn JR; White AE; Fox SC; Dovlatova N; Heptinstall S
Platelets; 2011; 22(7):504-15. PubMed ID: 21591981
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
